STOCK TITAN

Roivant (NASDAQ: ROIV) president exercises 200K options, sells shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Roivant Sciences Ltd. president and Immunovant CEO Eric Venker reported an exercise-and-sale transaction in the company’s common shares. He exercised stock options to acquire 200,000 common shares at $3.85 per share and sold 200,000 common shares in open-market transactions at a weighted average price of $29.59 per share, with individual trade prices ranging from $29.33 to $29.88. Following these transactions, he directly holds 1,647,546 common shares. A related stock option award to purchase common shares is described as fully vested.

Positive

  • None.

Negative

  • None.
Insider Venker Eric
Role President & Immunovant CEO
Sold 200,000 shs ($5.92M)
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) 200,000 $0.00 --
Exercise Common Shares 200,000 $3.85 $770K
Sale Common Shares 200,000 $29.59 $5.92M
Holdings After Transaction: Stock Option (Right to Buy) — 4,644,834 shares (Direct, null); Common Shares — 1,847,546 shares (Direct, null)
Footnotes (1)
  1. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.33 to $29.88, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. Reflects an award of stock options to purchase Common Shares that is fully vested.
Shares sold 200,000 shares Common shares sold in open-market transactions on 2026-04-20
Weighted average sale price $29.59 per share Common share sales, price range $29.33–$29.88
Shares held after transactions 1,647,546 shares Direct beneficial ownership of common shares after 2026-04-20
Options exercised 200,000 options Stock options exercised into common shares at $3.85 per share
Option exercise price $3.85 per share Exercise price for 200,000 stock options converted to common shares
Remaining stock options 4,644,834 options Stock options outstanding after the reported derivative transaction
Option expiration date 2032-04-19 Expiration date for the reported stock option series
Sale price range $29.33–$29.88 per share Price range for individual trades within the 200,000-share sale
weighted average price financial
"The price reported in column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
stock options financial
"Reflects an award of stock options to purchase Common Shares that is fully vested."
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
fully vested financial
"Reflects an award of stock options to purchase Common Shares that is fully vested."
derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Venker Eric

(Last)(First)(Middle)
C/O ROIVANT SCIENCES LTD.
7TH FLOOR, 50 BROADWAY

(Street)
LONDONSW1H 0DB

(City)(State)(Zip)

UNITED KINGDOM

(Country)
2. Issuer Name and Ticker or Trading Symbol
Roivant Sciences Ltd. [ ROIV ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
President & Immunovant CEO
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/20/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Shares04/20/2026M200,000A$3.851,847,546D
Common Shares04/20/2026S200,000D$29.59(1)1,647,546D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$3.8504/20/2026M200,000 (2)04/19/2032Common Stock200,000$04,644,834D
Explanation of Responses:
1. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.33 to $29.88, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range.
2. Reflects an award of stock options to purchase Common Shares that is fully vested.
Remarks:
By: /s/ Jo Chen, as Attorney-in-Fact for Eric Venker04/22/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Eric Venker report at Roivant Sciences (ROIV)?

Eric Venker reported exercising stock options for 200,000 Roivant common shares and selling 200,000 common shares. The filing shows a combined exercise-and-sale pattern on the same date, reflecting option exercise and subsequent open-market sales of the acquired shares.

At what prices did Eric Venker sell Roivant Sciences (ROIV) shares?

The reported weighted average sale price was $29.59 per share. Footnotes explain that the 200,000 common shares were sold in multiple transactions at prices ranging from $29.33 to $29.88 per share, inclusive, across the open market on the transaction date.

How many Roivant Sciences (ROIV) shares does Eric Venker hold after this Form 4?

After the reported transactions, Eric Venker directly holds 1,647,546 Roivant common shares. This figure reflects his position following the 200,000-share option exercise and the 200,000-share open-market sale disclosed in the Form 4 filing for the same date.

What stock options did Eric Venker exercise in the Roivant Sciences (ROIV) filing?

He exercised stock options covering 200,000 underlying common shares at an exercise price of $3.85 per share. A footnote states this award of stock options to purchase common shares is fully vested, meaning the entire option grant was exercisable at the time of the transaction.

Does Eric Venker still hold Roivant Sciences (ROIV) stock options after this transaction?

Yes. After exercising 200,000 options, the filing shows 4,644,834 stock options remaining. These options relate to rights to buy Roivant common shares and carry an expiration date in 2032 for the specific option series referenced in the derivative transaction.